Journal article

MM-128: Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies

Hang Quach, Ajay Nooka, Olga Samoylova, Christopher Venner, Kihyun Kim, Thierry Facon, Andrew Spencer, Saad Usmani, Sebastian Grosicki, Kenshi Suzuki, Sosana Delimpasi, Katja Weisel, Mihaela Obreja, Anita Zahlten-Kumeli, Maria-Victoria Mateos

Clinical Lymphoma Myeloma and Leukemia | Elsevier BV | Published : 2020

University of Melbourne Researchers